(513) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
(939) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
(2384) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
Ulcer healing · pressure ulcer
It is very uncertain whether platelet‐rich growth factor + hyaluronic acid changes complete ulcer healing compared with platelet‐rich growth factor (very low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · people with pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · people with pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in ulcer size · people with pressure ulcers
1 finding from 1 review
Time to complete wound healing ‐ not reported · pressure ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · pressure ulcer
1 finding from 1 review
Health‐related quality of life · pressure ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · pressure ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in ulcer size · pressure ulcer
It is very uncertain whether platelet‐rich growth factor + hyaluronic acid changes change in ulcer size compared with platelet‐rich growth factor (very low certainty).
1 finding from 1 review
Ulcer healing · people with pressure ulcers
It is very uncertain whether lysine hyaluronate changes complete ulcer healing compared with sodium hyaluronate (very low certainty).
1 finding from 1 review
Time to complete wound healing ‐ not reported · people with pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · people with pressure ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 19 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in overall survival (OS) ‐ Network (subnet 1) included 19 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 27 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention probably leads to lower progression‐free survival (PFS) ‐ Network (subnet 1) included 27… (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review
Intervention not reported
Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).
1 finding from 1 review